JP2011079828A5 - - Google Patents

Download PDF

Info

Publication number
JP2011079828A5
JP2011079828A5 JP2010227222A JP2010227222A JP2011079828A5 JP 2011079828 A5 JP2011079828 A5 JP 2011079828A5 JP 2010227222 A JP2010227222 A JP 2010227222A JP 2010227222 A JP2010227222 A JP 2010227222A JP 2011079828 A5 JP2011079828 A5 JP 2011079828A5
Authority
JP
Japan
Prior art keywords
alkyl
aryl
cycloalkyl
heterocyclyl
heteroaryl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2010227222A
Other languages
English (en)
Japanese (ja)
Other versions
JP5345117B2 (ja
JP2011079828A (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2011079828A publication Critical patent/JP2011079828A/ja
Publication of JP2011079828A5 publication Critical patent/JP2011079828A5/ja
Application granted granted Critical
Publication of JP5345117B2 publication Critical patent/JP5345117B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2010227222A 2005-07-20 2010-10-07 Hcvns3プロテアーゼ阻害剤 Active JP5345117B2 (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US70076405P 2005-07-20 2005-07-20
US60/700,764 2005-07-20
US72456605P 2005-10-07 2005-10-07
US60/724,566 2005-10-07

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2008522888A Division JP4621282B2 (ja) 2005-07-20 2006-07-14 Hcvns3プロテアーゼ阻害剤

Publications (3)

Publication Number Publication Date
JP2011079828A JP2011079828A (ja) 2011-04-21
JP2011079828A5 true JP2011079828A5 (enExample) 2011-08-11
JP5345117B2 JP5345117B2 (ja) 2013-11-20

Family

ID=37467463

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2008522888A Active JP4621282B2 (ja) 2005-07-20 2006-07-14 Hcvns3プロテアーゼ阻害剤
JP2010227222A Active JP5345117B2 (ja) 2005-07-20 2010-10-07 Hcvns3プロテアーゼ阻害剤

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2008522888A Active JP4621282B2 (ja) 2005-07-20 2006-07-14 Hcvns3プロテアーゼ阻害剤

Country Status (37)

Country Link
US (2) US7470664B2 (enExample)
EP (2) EP1924593B9 (enExample)
JP (2) JP4621282B2 (enExample)
KR (1) KR101296095B1 (enExample)
AR (1) AR057456A1 (enExample)
AT (1) ATE443075T1 (enExample)
AU (1) AU2006276189B9 (enExample)
BR (1) BRPI0613633A2 (enExample)
CA (1) CA2615022C (enExample)
CR (1) CR9621A (enExample)
CY (1) CY1109671T1 (enExample)
DE (1) DE602006009280D1 (enExample)
DK (1) DK1924593T3 (enExample)
DO (2) DOP2006000171A (enExample)
EA (1) EA013331B1 (enExample)
EC (1) ECSP088107A (enExample)
ES (2) ES2332821T3 (enExample)
GE (1) GEP20115248B (enExample)
GT (1) GT200600317A (enExample)
HN (1) HN2008000087A (enExample)
HR (1) HRP20090627T1 (enExample)
IL (1) IL188618A0 (enExample)
JO (1) JO2593B1 (enExample)
MA (1) MA30198B1 (enExample)
MX (1) MX2008000866A (enExample)
MY (1) MY142240A (enExample)
NO (1) NO20080879L (enExample)
NZ (1) NZ565223A (enExample)
PE (1) PE20070364A1 (enExample)
PL (1) PL1924593T3 (enExample)
PT (1) PT1924593E (enExample)
RS (1) RS51101B (enExample)
SG (1) SG164376A1 (enExample)
SI (1) SI1924593T1 (enExample)
TN (1) TNSN08033A1 (enExample)
TW (1) TWI387603B (enExample)
WO (2) WO2007015787A1 (enExample)

Families Citing this family (113)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003007697A (ja) * 2001-06-21 2003-01-10 Hitachi Kokusai Electric Inc 半導体装置の製造方法、基板処理方法および基板処理装置
MY140680A (en) 2002-05-20 2010-01-15 Bristol Myers Squibb Co Hepatitis c virus inhibitors
CA2606195C (en) * 2005-05-02 2015-03-31 Merck And Co., Inc. Hcv ns3 protease inhibitors
EP1905777B2 (en) * 2005-07-04 2018-06-27 Zannan Scitech Co., Ltd. Ruthenium complex ligand, ruthenium complex, carried ruthenium complex catalyst and the preparing methods and the use thereof
TWI387603B (zh) * 2005-07-20 2013-03-01 Merck Sharp & Dohme Hcv ns3蛋白酶抑制劑
KR101294467B1 (ko) 2005-07-25 2013-09-09 인터뮨, 인크. C형 간염 바이러스 복제의 신규 거대고리형 억제제
BRPI0614205A2 (pt) * 2005-08-01 2016-11-22 Merck & Co Inc composto, composição farmacêutica, e, uso de composto
DE602006019323D1 (de) * 2005-10-11 2011-02-10 Intermune Inc Verbindungen und verfahren zur inhibierung der replikation des hepatitis-c-virus
US7741281B2 (en) 2005-11-03 2010-06-22 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
GB0609492D0 (en) * 2006-05-15 2006-06-21 Angeletti P Ist Richerche Bio Therapeutic agents
GB0612423D0 (en) * 2006-06-23 2006-08-02 Angeletti P Ist Richerche Bio Therapeutic agents
RU2008152171A (ru) * 2006-07-05 2010-08-10 Интермьюн, Инк. (Us) Новые ингибиторы вирусной репликации гепатита с
US7935670B2 (en) 2006-07-11 2011-05-03 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
AU2007309488B2 (en) * 2006-10-24 2012-10-11 Merck Sharp & Dohme Corp. HCV NS3 protease inhibitors
US8377873B2 (en) * 2006-10-24 2013-02-19 Merck Sharp & Dohme Corp. HCV NS3 protease inhibitors
EP2079479B1 (en) * 2006-10-24 2014-11-26 Merck Sharp & Dohme Corp. Hcv ns3 protease inhibitors
CN101568346B (zh) * 2006-10-27 2015-11-25 默沙东公司 Hcv ns3蛋白酶抑制剂
MY164469A (en) * 2006-10-27 2017-12-15 Msd Italia Srl Hcv ns3 protease inhibitors
US8343477B2 (en) 2006-11-01 2013-01-01 Bristol-Myers Squibb Company Inhibitors of hepatitis C virus
US7772180B2 (en) 2006-11-09 2010-08-10 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7888464B2 (en) 2006-11-16 2011-02-15 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7763584B2 (en) 2006-11-16 2010-07-27 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8003604B2 (en) 2006-11-16 2011-08-23 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
GB0625345D0 (en) * 2006-12-20 2007-01-31 Angeletti P Ist Richerche Bio Therapeutic compounds
GB0625349D0 (en) * 2006-12-20 2007-01-31 Angeletti P Ist Richerche Bio Therapeutic compounds
AU2007335962B2 (en) * 2006-12-20 2012-09-06 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa Antiviral indoles
US20100143886A1 (en) 2007-03-09 2010-06-10 Ludmerer Steven W In vivo hcv resistance to anti-viral inhibitors
ATE490961T1 (de) * 2007-04-24 2010-12-15 Hoffmann La Roche Verfahren für hcv-proteasehemmerzwischenprodukt
JP2010528987A (ja) * 2007-05-03 2010-08-26 インターミューン・インコーポレーテッド C型肝炎ウイルス複製の新規大環状阻害剤
CL2008001381A1 (es) 2007-05-10 2008-11-03 Intermune Inc Y Array Biopharma Inc Compuestos derivados de tripeptidos que contienen heterociclos nitrogenados; composicion farmaceutica que comprende a dichos compuestos; y uso para tratar una infeccion de hepatitis c o vih.
EP2178886A1 (en) * 2007-07-17 2010-04-28 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. Macrocyclic indole derivatives for the treatment of hepatitis c infections
JP5433573B2 (ja) * 2007-07-19 2014-03-05 イステイチユート・デイ・リチエルケ・デイ・ビオロジア・モレコラーレ・ピ・アンジエレツテイ・エツセ・エルレ・エルレ 抗ウイルス剤としての大環状化合物
US8383583B2 (en) * 2007-10-26 2013-02-26 Enanta Pharmaceuticals, Inc. Macrocyclic, pyridazinone-containing hepatitis C serine protease inhibitors
MX2010005261A (es) * 2007-11-14 2010-10-15 Enanta Pharm Inc Inhibidores macrocíclicos de proteasa de serina de hepatitis c de tetrazolilo.
CL2008003384A1 (es) * 2007-11-14 2009-12-11 Enanta Pharm Inc Compuestos derivados de quinoxalina macrocíclica, inhibidores de serina proteasa; composicion farmaceutica que los comprende; y su uso en el tratamiento de la hepatitis c.
MX2010006518A (es) 2007-12-14 2010-08-10 Enanta Pharm Inc Inhibidores de serina proteasa de hepatitis c de oximil macrociclica.
US8273709B2 (en) 2007-12-14 2012-09-25 Enanta Pharmaceuticals, Inc. Triazole-containing macrocyclic HCV serine protease inhibitors
AU2008338273B2 (en) 2007-12-19 2014-10-02 Boehringer Ingelheim International Gmbh Viral polymerase inhibitors
WO2009085978A1 (en) 2007-12-20 2009-07-09 Enanta Pharceuticals, Inc. Bridged carbocyclic oxime hepatitis c virus serine protease inhibitors
CA2710144A1 (en) * 2007-12-21 2009-07-02 Avila Therapeutics, Inc. Hcv protease inhibitors and uses thereof
US8309685B2 (en) * 2007-12-21 2012-11-13 Celgene Avilomics Research, Inc. HCV protease inhibitors and uses thereof
US8293705B2 (en) * 2007-12-21 2012-10-23 Avila Therapeutics, Inc. HCV protease inhibitors and uses thereof
CN101951770B (zh) * 2007-12-21 2014-12-31 阿维拉制药公司 Hcv蛋白酶抑制剂和其用途
AU2015224437B2 (en) * 2007-12-21 2017-05-25 Celgene Avilomics Research, Inc. HCV protease inhibitors and uses thereof
US8202996B2 (en) 2007-12-21 2012-06-19 Bristol-Myers Squibb Company Crystalline forms of N-(tert-butoxycarbonyl)-3-methyl-L-valyl-(4R)-4-((7-chloro-4-methoxy-1-isoquinolinyl)oxy)-N- ((1R,2S)-1-((cyclopropylsulfonyl)carbamoyl)-2-vinylcyclopropyl)-L-prolinamide
KR20100118991A (ko) * 2008-02-04 2010-11-08 아이데닉스 파마슈티칼스, 인코포레이티드 매크로시클릭 세린 프로테아제 억제제
AU2009217551B2 (en) * 2008-02-25 2014-07-31 Msd Italia S.R.L. Therapeutic compounds
MX2010010276A (es) * 2008-03-20 2011-03-25 Enanta Pharm Inc Compuestos macrociclicos fluorinados como inhibidores del virus de hepatitis c.
BRPI0911260A2 (pt) * 2008-04-15 2015-09-29 Intermune Inc composto, composição farmacêutica, método de inibição de atividade da protease de ns3/ns4 in, vitro e usos de compostos
US8163921B2 (en) 2008-04-16 2012-04-24 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
JP2011518882A (ja) * 2008-04-28 2011-06-30 メルク・シャープ・エンド・ドーム・コーポレイション Hcvns3プロテアーゼ阻害剤
US7964560B2 (en) 2008-05-29 2011-06-21 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8044023B2 (en) 2008-05-29 2011-10-25 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
UA100436C2 (en) * 2008-07-22 2012-12-25 Mepk Шарп Энд Доме Корп. Macrocyclic quinoxaline compounds as hcv ns3 protease inhibitors
US8188137B2 (en) 2008-08-15 2012-05-29 Avila Therapeutics, Inc. HCV protease inhibitors and uses thereof
US8207341B2 (en) 2008-09-04 2012-06-26 Bristol-Myers Squibb Company Process or synthesizing substituted isoquinolines
US8563505B2 (en) 2008-09-29 2013-10-22 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8044087B2 (en) 2008-09-29 2011-10-25 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8283310B2 (en) 2008-12-15 2012-10-09 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
UY32325A (es) * 2008-12-19 2010-07-30 Gilead Sciences Inc Inhibidores de ns3 proteasa del vhc
CA2750227A1 (en) 2009-01-07 2010-07-15 Scynexis, Inc. Cyclosporine derivative for use in the treatment of hcv and hiv infection
WO2010082050A1 (en) 2009-01-16 2010-07-22 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. Macrocyclic and 7-aminoalkyl-substituted benzoxazocines for treatment of hepatitis c infections
AR075584A1 (es) * 2009-02-27 2011-04-20 Intermune Inc COMPOSICIONES TERAPEUTICAS QUE COMPRENDEN beta-D-2'-DESOXI-2'-FLUORO-2'-C-METILCITIDINA Y UN DERIVADO DE ACIDO ISOINDOL CARBOXILICO Y SUS USOS. COMPUESTO.
CA2758072A1 (en) 2009-04-08 2010-10-14 Idenix Pharmaceuticals, Inc. Macrocyclic serine protease inhibitors
JP5639155B2 (ja) * 2009-05-13 2014-12-10 エナンタ ファーマシューティカルズ インコーポレイテッド C型肝炎ウイルスインヒビターとしての大環状化合物
US8703700B2 (en) * 2009-05-22 2014-04-22 Sequoia Pharmaceuticals, Inc. Bimacrocylic HCV NS3 protease inhibitors
EP2459582B1 (en) 2009-07-30 2015-05-27 Merck Sharp & Dohme Corp. Hepatitis c virus ns3 protease inhibitors
JP2013501068A (ja) 2009-08-05 2013-01-10 アイディニックス ファーマシューティカルズ インコーポレイテッド 大環状セリンプロテアーゼ阻害剤
WO2011025849A1 (en) * 2009-08-27 2011-03-03 Merck Sharp & Dohme Corp. Processes for preparing protease inhibitors of hepatitis c virus
EA201290128A1 (ru) * 2009-09-28 2013-01-30 Интермьюн, Инк. Новые макроциклические ингибиторы репликации вируса гепатита с
WO2011049908A2 (en) 2009-10-19 2011-04-28 Enanta Pharmaceuticals, Inc. Bismacrokyclic compounds as hepatitis c virus inhibitors
RU2535664C2 (ru) 2010-01-27 2014-12-20 Аб Фарма Лтд Полигетероциклические соединения, используемые в качестве высокоэффективных ингибиторов вируса гепатита с
JP2013529627A (ja) 2010-06-24 2013-07-22 パンメド リミテッド ヒドロキシクロロキンまたはヒドロキシクロロキンおよび抗ウイルス剤の組合せを使用するc型肝炎ウイルス関連疾患の処置
KR102163902B1 (ko) 2010-09-21 2020-10-12 이난타 파마슈티칼스, 인코포레이티드 매크로사이클릭 프롤린 유도된 hcv 세린 프로테아제 억제제
CN103328466B (zh) 2010-11-01 2016-08-03 Rfs制药公司 Hcv ns3蛋白酶抑制剂
CA2817365A1 (en) 2010-12-14 2012-06-21 Merck Sharp & Dohme Corp. Process and intermediates for preparing macrolactams
TW201309690A (zh) 2011-02-10 2013-03-01 Idenix Pharmaceuticals Inc 巨環絲胺酸蛋白酶抑制劑,其醫藥組合物及其於治療hcv感染之用途
US8957203B2 (en) 2011-05-05 2015-02-17 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8691757B2 (en) 2011-06-15 2014-04-08 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
AU2012269643A1 (en) * 2011-06-16 2014-02-06 AB Pharma Ltd. Macrocyclic heterocyclic compound for inhibiting hepatitis C virus and preparation and use thereof
US8912141B2 (en) 2011-06-23 2014-12-16 Panmed Ltd. Treatment of hepatitis C virus
JP2014521750A (ja) 2011-08-19 2014-08-28 メルク・シャープ・アンド・ドーム・コーポレーション マクロラクタムを調製するための方法および中間体
US8466159B2 (en) 2011-10-21 2013-06-18 Abbvie Inc. Methods for treating HCV
US8492386B2 (en) 2011-10-21 2013-07-23 Abbvie Inc. Methods for treating HCV
SE1450131A1 (sv) 2011-10-21 2014-05-07 Abbvie Inc DAA-kombinationsbehandling (t.ex. med ABT-072 eller ABT-333)för användning vid behandling av HCV
SE1450130A1 (sv) 2011-10-21 2014-05-07 Abbvie Inc Förfaranden för att behandla hcv innefattande minst två direktverkande antivirala agenser, ribavirin men inte interferon
BR112014010545A2 (pt) * 2011-10-31 2017-05-02 Merk Sharp & Dohme Corp composição farmacêutica, método para tratar um paciente infectado com vírus da hepatite c, uso de uma composição
ES2563479T3 (es) * 2012-01-11 2016-03-15 Abbvie Inc. Procedimientos para elaborar inhibidores de proteasa de VHC
CA2858814A1 (en) 2012-01-12 2013-07-18 Rfs Pharma, Llc Hcv ns3 protease inhibitors
CN102617705B (zh) 2012-02-16 2014-12-31 上海纬诺医药科技有限公司 抑制丙肝病毒复制的大环类化合物
UA119315C2 (uk) 2012-07-03 2019-06-10 Гіліад Фармассет Елелсі Інгібітори вірусу гепатиту с
TW201408669A (zh) 2012-08-08 2014-03-01 Merck Sharp & Dohme Hcv ns3蛋白酶抑制劑
ES2613766T3 (es) 2012-10-19 2017-05-25 Bristol-Myers Squibb Company Derivados de carbamato de hexadecahidrociclopropa(e)pirrolo(1,2-a)(1,4)diazaciclopentadecinilo sustituidos con 9-metilo como inhibidores de la proteasa no estructural 3 (NS3) para el tratamiento de infecciones del virus de la hepatitis C
US9643999B2 (en) 2012-11-02 2017-05-09 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US9598433B2 (en) 2012-11-02 2017-03-21 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US9334279B2 (en) 2012-11-02 2016-05-10 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US9409943B2 (en) 2012-11-05 2016-08-09 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
WO2014121417A1 (en) 2013-02-07 2014-08-14 Merck Sharp & Dohme Corp. Tetracyclic heterocycle compounds and methods of use thereof for the treatment of hepatitis c
WO2014121418A1 (en) 2013-02-07 2014-08-14 Merck Sharp & Dohme Corp. Tetracyclic heterocycle compounds and methods of use thereof for the treatment of hepatitis c
EP2964664B1 (en) 2013-03-07 2017-01-11 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
US11484534B2 (en) 2013-03-14 2022-11-01 Abbvie Inc. Methods for treating HCV
US9708354B2 (en) 2013-03-15 2017-07-18 Cerenis Therapeutics Holding Sa Methods for the synthesis of sphingomyelins and dihydrosphingomyelins
CA2902569A1 (en) 2013-03-15 2014-09-18 Gilead Sciences, Inc. Inhibitors of hepatitis c virus
KR20150132188A (ko) * 2013-03-15 2015-11-25 세레니스 쎄라퓨틱스 홀딩 에스에이 스핑고미엘린 및 디히드로스핑고미엘린의 합성 방법
EP3057926A4 (en) 2013-10-18 2017-07-12 Merck Sharp & Dohme Corp. Methods and intermediates for preparing macrolactams
CN109689063A (zh) 2016-04-28 2019-04-26 埃默里大学 含有炔烃的核苷酸和核苷治疗组合物及其相关用途
WO2017197036A1 (en) 2016-05-10 2017-11-16 C4 Therapeutics, Inc. Spirocyclic degronimers for target protein degradation
ES2989988T3 (es) 2016-05-10 2024-11-28 C4 Therapeutics Inc Degronímeros heterorocíclicos para la degradación de proteínas diana
CN109790143A (zh) 2016-05-10 2019-05-21 C4医药公司 用于靶蛋白降解的胺连接的c3-戊二酰亚胺降解决定子体
CN109641874A (zh) 2016-05-10 2019-04-16 C4医药公司 用于靶蛋白降解的c3-碳连接的戊二酰亚胺降解决定子体
CN118440096A (zh) 2017-06-20 2024-08-06 C4医药公司 用于蛋白降解的n/o-连接的降解决定子和降解决定子体
US20230218644A1 (en) 2020-04-16 2023-07-13 Som Innovation Biotech, S.A. Compounds for use in the treatment of viral infections by respiratory syndrome-related coronavirus
US12083099B2 (en) 2020-10-28 2024-09-10 Accencio LLC Methods of treating symptoms of coronavirus infection with viral protease inhibitors

Family Cites Families (79)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3480613A (en) * 1967-07-03 1969-11-25 Merck & Co Inc 2-c or 3-c-alkylribofuranosyl - 1-substituted compounds and the nucleosides thereof
FR2722210B1 (fr) * 1994-07-08 1996-08-14 Rhone Poulenc Rorer Sa Nouvelles streptogramines et procede de preparation de streptogramines par mutasynthese
US6128582A (en) 1996-04-30 2000-10-03 Vertex Pharmaceuticals Incorporated Molecules comprising an IMPDH-like binding pocket and encoded data storage medium capable of graphically displaying them
GB9623908D0 (en) 1996-11-18 1997-01-08 Hoffmann La Roche Amino acid derivatives
GB9707659D0 (en) 1997-04-16 1997-06-04 Peptide Therapeutics Ltd Hepatitis C NS3 Protease inhibitors
PT1012180E (pt) 1997-08-11 2005-04-29 Boehringer Ingelheim Ca Ltd Analogos de peptidos inibidores da hepatite c
PT1003775E (pt) 1997-08-11 2005-07-29 Boehringer Ingelheim Ca Ltd Peptidos inibidores da hepatite c
IT1299134B1 (it) 1998-02-02 2000-02-29 Angeletti P Ist Richerche Bio Procedimento per la produzione di peptidi con proprieta' inibitrici della proteasi ns3 del virus hcv, peptidi cosi' ottenibili e peptidi
WO1999043691A1 (en) 1998-02-25 1999-09-02 Emory University 2'-fluoronucleosides
GB9806815D0 (en) 1998-03-30 1998-05-27 Hoffmann La Roche Amino acid derivatives
DE69934104T2 (de) 1998-03-31 2007-06-28 Vertex Pharmaceuticals Inc., Cambridge Inhibitoren von serinproteasen, insbesondere von hepatitis c virus ns3 protease
GB9812523D0 (en) 1998-06-10 1998-08-05 Angeletti P Ist Richerche Bio Peptide inhibitors of hepatitis c virus ns3 protease
EP1106626B1 (en) 1998-08-10 2003-05-28 Hokkaido Electric Power Company, Incorporated Process for the preparation of regular glycopeptides
US6323180B1 (en) * 1998-08-10 2001-11-27 Boehringer Ingelheim (Canada) Ltd Hepatitis C inhibitor tri-peptides
JP2002528499A (ja) 1998-10-29 2002-09-03 ブリストル−マイヤーズ スクイブ カンパニー Impdh酵素のインヒビターであるアミノ核誘導化合物
US6608027B1 (en) * 1999-04-06 2003-08-19 Boehringer Ingelheim (Canada) Ltd Macrocyclic peptides active against the hepatitis C virus
UA74546C2 (en) * 1999-04-06 2006-01-16 Boehringer Ingelheim Ca Ltd Macrocyclic peptides having activity relative to hepatitis c virus, a pharmaceutical composition and use of the pharmaceutical composition
DK1196414T3 (da) 1999-06-25 2003-11-24 Vertex Pharma Prolægemiddel af carbamathæmmer for IMPDH
HUP0202263A3 (en) 1999-12-27 2003-02-28 Japan Tobacco Inc Benzimidazole, indole and imidazo-pyridine derivatives and pharmaceutical compositions containing them
US6455508B1 (en) 2000-02-15 2002-09-24 Kanda S. Ramasamy Methods for treating diseases with tirazole and pyrrolo-pyrimidine ribofuranosyl nucleosides
US6495677B1 (en) 2000-02-15 2002-12-17 Kanda S. Ramasamy Nucleoside compounds
CN1427722A (zh) * 2000-02-18 2003-07-02 希拉生物化学股份有限公司 用核苷类似物治疗或预防黄病毒感染的方法
US6727267B2 (en) 2000-04-05 2004-04-27 Tularik Inc. NS5B HVC polymerase inhibitors
WO2001077113A2 (en) 2000-04-05 2001-10-18 Schering Corporation Macrocyclic ns3-serine protease inhibitors of hepatitis c virus comprising n-cyclic p2 moieties
ATE414520T1 (de) 2000-04-13 2008-12-15 Pharmasset Inc 3 oder 2 hydroxymethyl substituierte nucleoside derivate und ihre verwendung zur behandlung von virusinfektionen
MY164523A (en) 2000-05-23 2017-12-29 Univ Degli Studi Cagliari Methods and compositions for treating hepatitis c virus
MXPA02011691A (es) 2000-05-26 2004-05-17 Idenix Cayman Ltd Metodos y composiciones para el tratamiento de flavivirus y pestivirus.
US6448281B1 (en) 2000-07-06 2002-09-10 Boehringer Ingelheim (Canada) Ltd. Viral polymerase inhibitors
GB0017676D0 (en) 2000-07-19 2000-09-06 Angeletti P Ist Richerche Bio Inhibitors of viral polymerase
JP3943015B2 (ja) * 2000-08-10 2007-07-11 トラスティーズ オブ ボストン カレッジ リサイクル可能メタセシス触媒
US6955174B2 (en) * 2000-08-18 2005-10-18 Uryovascular Systems, Inc. Cryotherapy method for detecting and treating vulnerable plaque
US20030008841A1 (en) 2000-08-30 2003-01-09 Rene Devos Anti-HCV nucleoside derivatives
WO2002020497A1 (en) 2000-09-01 2002-03-14 Shionogi & Co., Ltd. Compounds having anti-hepatitis c virus effect
KR20040028657A (ko) 2000-10-18 2004-04-03 파마셋, 리미티드 바이러스 감염 및 비정상적인 세포 증식의 치료를 위한변형된 뉴클레오시드
CN1301994C (zh) 2000-12-12 2007-02-28 先灵公司 作为c型肝炎病毒ns3-丝氨酸蛋白酶抑制剂的二芳基肽
WO2002048116A2 (en) 2000-12-13 2002-06-20 Bristol-Myers Squibb Pharma Company Inhibitors of hepatitis c virus ns3 protease
JP2005502580A (ja) 2000-12-15 2005-01-27 フアーマセツト・リミテツド フラビウィルス感染治療用抗ウィルス薬
EP1346724A4 (en) 2000-12-26 2004-11-17 Mitsubishi Pharma Corp AGENT FOR TREATING HEPATITIS C
EP1355916B1 (en) 2001-01-22 2007-01-10 Merck & Co., Inc. Nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase
GB0114286D0 (en) * 2001-06-12 2001-08-01 Hoffmann La Roche Nucleoside Derivatives
CN100542612C (zh) 2001-08-14 2009-09-23 特拉维夫大学未来技术研发有限公司 类脂化糖胺聚糖颗粒及其在诊断和治疗用药物和基因传递中的应用
WO2003026675A1 (en) 2001-09-28 2003-04-03 Idenix (Cayman) Limited Methods and compositions for treating flaviviruses and pestiviruses using 4'-modified nucleoside
WO2003026589A2 (en) 2001-09-28 2003-04-03 Idenix (Cayman) Limited Methods and compositions for treating hepatitis c virus using 4'-modified nucleosides
US6867185B2 (en) * 2001-12-20 2005-03-15 Bristol-Myers Squibb Company Inhibitors of hepatitis C virus
WO2003062192A1 (en) 2002-01-17 2003-07-31 Smithkline Beecham Corporation Cycloalkyl ketoamides derivatives useful as cathepsin k inhibitors
GB0201179D0 (en) 2002-01-18 2002-03-06 Angeletti P Ist Richerche Bio Therapeutic agents
CA2369711A1 (en) * 2002-01-30 2003-07-30 Boehringer Ingelheim (Canada) Ltd. Macrocyclic peptides active against the hepatitis c virus
US6828301B2 (en) 2002-02-07 2004-12-07 Boehringer Ingelheim International Gmbh Pharmaceutical compositions for hepatitis C viral protease inhibitors
CA2474563C (en) 2002-02-13 2010-11-09 Merck & Co., Inc. Methods of inhibiting orthopoxvirus replication with nucleoside compounds
KR20050006221A (ko) * 2002-05-06 2005-01-15 제네랩스 테크놀로지스, 인코포레이티드 C형 간염 바이러스 감염 치료용의 뉴클레오시드 유도체
MY140680A (en) 2002-05-20 2010-01-15 Bristol Myers Squibb Co Hepatitis c virus inhibitors
US20070004669A1 (en) 2002-06-21 2007-01-04 Carroll Steven S Nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase
WO2004003138A2 (en) 2002-06-27 2004-01-08 Merck & Co., Inc. Nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase
JP5087211B2 (ja) 2002-06-28 2012-12-05 イデニクス(ケイマン)リミテツド フラビウィルス感染治療のための2′および3′−ヌクレオシドプロドラッグ
MXPA04012802A (es) 2002-06-28 2005-04-19 Idenix Cayman Ltd Ester 2'-c-metil-3'-o-l-valina de ribofuranosil-citidina para el tratamiento de infecciones por flaviviridae.
KR20050048544A (ko) 2002-06-28 2005-05-24 이데닉스 (케이만) 리미티드 플라비비리다에 감염 치료용의 변형된 2' 및3'-뉴클레오사이드 프로드럭
WO2004007512A2 (en) 2002-07-16 2004-01-22 Merck & Co., Inc. Nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase
AU2003254657A1 (en) 2002-07-25 2004-02-16 Micrologix Biotech Inc. Anti-viral 7-deaza d-nucleosides and uses thereof
MXPA05001298A (es) 2002-08-01 2005-11-04 Pharmasset Inc Compuestos con el sistema biciclo[4.2.1] nonano para el tratamiento de infecciones por flaviviridae.
US20050075279A1 (en) 2002-10-25 2005-04-07 Boehringer Ingelheim International Gmbh Macrocyclic peptides active against the hepatitis C virus
WO2004072243A2 (en) * 2003-02-07 2004-08-26 Enanta Pharmaceuticals, Inc. Macrocyclic hepatitis c serine protease inhibitors
US20040254159A1 (en) * 2003-02-27 2004-12-16 Hasvold Lisa A. Heterocyclic kinase inhibitors
EP1601685A1 (en) * 2003-03-05 2005-12-07 Boehringer Ingelheim International GmbH Hepatitis c inhibiting compounds
MXPA05010338A (es) * 2003-04-02 2005-11-17 Boehringer Ingelheim Int Composiciones farmaceuticas para inhibidores de la proteasa del virus de la hepatitis c.
WO2004094452A2 (en) * 2003-04-16 2004-11-04 Bristol-Myers Squibb Company Macrocyclic isoquinoline peptide inhibitors of hepatitis c virus
US7176208B2 (en) * 2003-04-18 2007-02-13 Enanta Pharmaceuticals, Inc. Quinoxalinyl macrocyclic hepatitis C serine protease inhibitors
AR044129A1 (es) 2003-05-06 2005-08-24 Altana Pharma Ag Compuestos intermedios de imidazopiridina. proceso de preparacion.
UA83046C2 (ru) 2003-05-21 2008-06-10 Берингер Ингельхайм Интернациональ Гмбх Соединения как ингибиторы вируса гепатита с, фармацевтическая композиция на их основе
US6955184B2 (en) 2003-05-29 2005-10-18 Honeywell International, Inc. Pneumatic generator system for simulating operating conditions of an aircraft
MXPA05013452A (es) * 2003-06-19 2006-03-09 Hoffmann La Roche Proceso para preparar derivados de 4'-azidonucleosido.
US7125845B2 (en) 2003-07-03 2006-10-24 Enanta Pharmaceuticals, Inc. Aza-peptide macrocyclic hepatitis C serine protease inhibitors
AP2006003763A0 (en) 2004-03-30 2006-10-31 Intermune Inc Macrocyclic compounds as inhibitors of viral replication
TWI387603B (zh) * 2005-07-20 2013-03-01 Merck Sharp & Dohme Hcv ns3蛋白酶抑制劑
GB0519797D0 (en) 2005-09-29 2005-11-09 Istituto Di Ricerche D Biolog Therapeutic agents
GB0609492D0 (en) 2006-05-15 2006-06-21 Angeletti P Ist Richerche Bio Therapeutic agents
WO2008019303A2 (en) 2006-08-04 2008-02-14 Enanta Pharmaceuticals, Inc. Pyridazinonyl macrocyclic hepatitis c serine protease inhibitors
CN101568346B (zh) 2006-10-27 2015-11-25 默沙东公司 Hcv ns3蛋白酶抑制剂
CL2008003384A1 (es) 2007-11-14 2009-12-11 Enanta Pharm Inc Compuestos derivados de quinoxalina macrocíclica, inhibidores de serina proteasa; composicion farmaceutica que los comprende; y su uso en el tratamiento de la hepatitis c.
MX2010005261A (es) 2007-11-14 2010-10-15 Enanta Pharm Inc Inhibidores macrocíclicos de proteasa de serina de hepatitis c de tetrazolilo.

Similar Documents

Publication Publication Date Title
JP2011079828A5 (enExample)
CA2615022A1 (en) Hcv ns3 protease inhibitors
RU2008107972A (ru) Макроциклические пептиды в качестве ингибиторов ns3-протеазы hcv
JP2013514359A5 (enExample)
JP2005529069A5 (enExample)
JP2011520906A5 (enExample)
JP2014503516A5 (enExample)
JP2012528166A5 (enExample)
RU2015123641A (ru) 2-алкинилзамещенные производные нуклеозидов, предназначенные для лечения вирусных заболеваний
JP2008509218A5 (enExample)
JP2013538235A5 (enExample)
JP2012528161A5 (enExample)
JP2012504129A5 (enExample)
HRP20140370T1 (hr) 1'-supstituirani-karba-nukleozid prolijekovi za antivirusni tretman
JP2012504632A5 (enExample)
JP2007535491A5 (enExample)
JP2012504132A5 (enExample)
JP2012512169A5 (enExample)
JP2014504643A5 (enExample)
JP2013533317A5 (enExample)
JP2013521279A5 (enExample)
JP2010513523A5 (enExample)
WO2005077969A3 (en) Inhibitors of serine proteases, particularly hcv ns3-ns4a protease
HRP20160083T1 (hr) Makrocikliäśki inhibitori serinske proteaze virusa hepatitisa c izvedeni iz prolina
JP2011511841A5 (enExample)